---

---

KemPharm Inc

KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

(0.0% 1d) (-2.4% 1m) (-64.7% 1y) (0.0% 2d) (-3.4% 3d) (-2.4% 7d) (-38.72% volume)
Earnings Calendar:
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea   treatment   profitable  

add to watch list email alert is off

Price chart

% (High / Open) change chart

---

Press-releases

Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Published: 2022-06-08 (Crawled : 22:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -7.57% | O: -0.61% H: 2.06% C: -0.21%
report results publication

---

Orphazyme Announces Publication of 2021 Financial Results and Annual Report
Published: 2022-06-07 (Crawled : 22:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -10.32% | O: -0.99% H: 2.4% C: -2.0%
report results publication

---

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm
Published: 2022-05-31 (Crawled : 17:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -3.62% | O: 0.64% H: 1.69% C: -1.91%

---

Updated Financial Calendar for 2022
Published: 2022-05-16 (Crawled : 13:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| 5.61% | O: -3.04% H: 10.84% C: 5.78%
for

---

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
Published: 2022-05-16 (Crawled : 01:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| 5.61% | O: -3.04% H: 10.84% C: 5.78%
acquisition rare disease

---

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.
Published: 2022-05-15 (Crawled : 00:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| 5.61% | O: -3.04% H: 10.84% C: 5.78%

---

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
Published: 2022-03-16 (Crawled : 12:00) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -11.72% | O: 1.37% H: 3.47% C: 1.93%
adlarity fda fda approval derm approval system one transdermal system

---

Central Nervous System (CNS) Stimulant Drugs Market to grow at a CAGR of 5.74 by 2026 | Rise in CNS Disorders to Boost Growth | 17000+ Technavio Reports
Published: 2022-03-14 (Crawled : 16:00) - prnewswire.com
GSK | News | $43.35 -0.8% -0.16% | |

Health Technology

| 6.71% | O: 0.42% H: 0.0% C: 0.0%
NVS | News | $84.17 -1.3% 0.12% | |

Health Technology

| 2.46% | O: 0.54% H: 0.0% C: 0.0%
ENDP | $0.71 85.33% 2.54% | |

Health Technology

| -69.4% | O: -1.72% H: 3.51% C: -5.26%
GLAXF | News | $21.99 4.22% | |

Health Technology

| 14.89% | O: 9.61% H: 0.0% C: -0.57%
BIIB | $202.51 -5.18% 1.43% | |

Health Technology

| 2.45% | O: 0.47% H: 1.48% C: -2.43%
NVSEF | News | $84.85 1.0% | |

Health Technology

| 1.07% | O: -3.28% H: 0.0% C: 0.0%
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -13.58% | O: 0.0% H: 1.34% C: -4.4%
TMO | News | $535.77 -1.45% -1.84% | |

Health Technology

| 0.16% | O: -1.31% H: 0.0% C: 0.0%
JAZZ | News | $155.24 -0.93% 0.0% | |

Health Technology

| 0.36% | O: 0.1% H: 1.14% C: -0.59%
ALPMF | News | $16.71 5.56% | |

Health Technology

| 6.43% | O: 0.7% H: 0.0% C: 0.0%
SNYNF | News | $108.84 4.15% | |

Health Technology

| 3.0% | O: -2.53% H: 0.0% C: -0.08%
ALPMY | News | $16.14 1.19% | |

Manufacturing

| 2.87% | O: 2.42% H: 0.31% C: -0.47%
VTRS | News | $10.9 -1.54% 1.19% | |

Health Technology

| 10.83% | O: 1.4% H: 1.08% C: -3.44%
SNY | News | $52.14 -0.88% -0.38% | |

Health Technology

| 1.09% | O: -3.24% H: 0.0% C: 0.0%
order drug system nervous system report growth

---

KemPharm to Report Fourth Quarter and Full-Year 2021 Results
Published: 2022-03-10 (Crawled : 12:30) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -18.56% | O: 0.18% H: 0.99% C: -2.52%
report results

---

KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
KMPH | $4.52 -3.42% 0.22% | |

Manufacturing

| -47.23% | O: -9.75% H: 3.23% C: -0.91%
trial results topline

---

See all

---

Your Today's Watch List

Sign in to create a watchlist

---

Last 48 Hours Insiders Buying

ALTG P 3227 | $9.29 -2.52% 0.0% | |

Distribution Services

| 01:40
SKIL P 30000 | $3.61 -6.96% 2.22% | |

Information

| 23:50
CAMP P 20000 | $4.65 -1.27% 0.86% | |

Electronic Technology

| 16:00

---